Article Details

CTI BioPharma Announces Acceptance of NDA Granted with Priority Review of Pacritinib for ...

Retrieved on: 2021-06-01 10:52:30

Tags for this article:

Click the tags to see associated articles and topics

CTI BioPharma Announces Acceptance of NDA Granted with Priority Review of Pacritinib for .... View article details on hiswai:

Excerpt

SEATTLE, June 1, 2021 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that the U.S. Food and Drug Administration (FDA) ...

Article found on: www.prnewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up